LENZ Therapeutics, Inc. (LENZ)
3.60
-0.19
(-5.01%)
USD |
NASDAQ |
Oct 07, 10:44
LENZ Therapeutics Enterprise Value : -100.36M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | -100.36M |
| October 05, 2026 | -106.65M |
| October 02, 2026 | -106.96M |
| October 01, 2026 | -100.36M |
| September 30, 2026 | -98.79M |
| September 29, 2026 | -98.16M |
| September 28, 2026 | -95.02M |
| September 25, 2026 | -96.44M |
| September 24, 2026 | -102.56M |
| September 23, 2026 | -101.31M |
| September 22, 2026 | -89.68M |
| September 21, 2026 | -91.25M |
| September 18, 2026 | -91.57M |
| September 17, 2026 | -89.68M |
| September 16, 2026 | -89.37M |
| September 15, 2026 | -86.54M |
| September 14, 2026 | -79.00M |
| September 11, 2026 | -77.43M |
| September 10, 2026 | -71.15M |
| September 09, 2026 | -65.18M |
| September 08, 2026 | -51.98M |
| September 04, 2026 | -32.19M |
| September 03, 2026 | -36.27M |
| September 02, 2026 | -37.22M |
| September 01, 2026 | -55.12M |
| Date | Value |
|---|---|
| August 31, 2026 | -55.75M |
| August 28, 2026 | -58.89M |
| August 27, 2026 | -68.32M |
| August 26, 2026 | -69.26M |
| August 25, 2026 | -72.72M |
| August 24, 2026 | -75.23M |
| August 21, 2026 | -72.40M |
| August 20, 2026 | -73.03M |
| August 19, 2026 | -64.86M |
| August 18, 2026 | -69.58M |
| August 17, 2026 | -68.95M |
| August 14, 2026 | -70.83M |
| August 13, 2026 | -74.92M |
| August 12, 2026 | -61.09M |
| August 11, 2026 | -55.75M |
| August 10, 2026 | -51.04M |
| August 07, 2026 | -51.04M |
| August 06, 2026 | -55.44M |
| August 05, 2026 | -53.87M |
| August 04, 2026 | -60.78M |
| August 03, 2026 | -62.51M |
| July 31, 2026 | -52.92M |
| July 30, 2026 | -38.47M |
| July 29, 2026 | -39.73M |
| July 28, 2026 | -34.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Impact BioMedical, Inc. | 43.22M |
| Enveric Biosciences, Inc. | -2.510M |
| Liquidia Corp. | 2.207B |
| Aquestive Therapeutics, Inc. | 629.20M |
| ANI Pharmaceuticals, Inc. | 1.878B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.92M |
| Revenue (Quarterly) | 5.486M |
| Total Expenses (Quarterly) | 37.40M |
| EPS Diluted (Quarterly) | -1.017 |
| Gross Profit Margin (Quarterly) | 94.90% |
| Profit Margin (Quarterly) | -581.8% |
| Earnings Yield | -113.4% |
| Normalized Earnings Yield | -113.36 |